Share on StockTwits

Ampio Pharmaceuticals (NASDAQ:AMPE) was downgraded by research analysts at Jefferies Group from a “buy” rating to a “hold” rating in a report released on Friday, TheFlyOnTheWall.com reports.

Shares of Ampio Pharmaceuticals (NASDAQ:AMPE) opened at 5.66 on Friday. Ampio Pharmaceuticals has a one year low of $5.07 and a one year high of $10.86. The stock’s 50-day moving average is $6.75 and its 200-day moving average is $7.01. The company’s market cap is $294.2 million.

Ampio Pharmaceuticals (NASDAQ:AMPE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.07. On average, analysts predict that Ampio Pharmaceuticals will post $-1.05 earnings per share for the current fiscal year.

A number of other firms have also recently commented on AMPE. Analysts at Aegis reiterated a “buy” rating on shares of Ampio Pharmaceuticals in a research note on Thursday.

Ampio Pharmaceuticals, Inc (NASDAQ:AMPE) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.